Translational Development Acquisition Corp. Ordinary Shares (TDAC) — Cash Flow-to-Debt Ratio
Translational Development Acquisition Corp. Ordinary Shares (TDAC) has a Cash Flow-to-Debt Ratio of -0.19x as of September 2025, meaning its operating cash flow of $-1.24 Million could theoretically repay 0% of its total liabilities ($6.46 Million) in one year. See TDAC FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Translational Development Acquisition Corp. Ordinary Shares Cash Flow-to-Debt Ratio (2022–2024)
Historical debt coverage capacity for Translational Development Acquisition Corp. Ordinary Shares across 3 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Translational Development Acquisition Co.
Annual Cash Flow-to-Debt Ratio for Translational Development Acquisition Corp. Ordinary Shares (2022–2024)
Year-by-year debt coverage analysis for Translational Development Acquisition Corp. Ordinary Shares. Check earnings quality score of Translational Development Acquisition Co to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.14x | $-851.45K | $6.25 Million | ▼ -33948.4% |
| 2023 | 0.00x | $-204.00 | $509.68K | ▲ +99.8% |
| 2022 | -0.21x | $-97.16K | $459.34K | — |